Baxter Intl Inc Stock Price, News & Analysis

Baxter International (NYSE:BAX) unveiled its first voice-activated technology, the Voalte Linq device powered by Scotty assistant, at HIMSS25. This lightweight, wearable badge integrates with Baxter's connected care portfolio, including Voalte Mobile and Voalte Nurse Call systems.

The technology aims to streamline hospital communication through voice commands activated by saying 'Hey Scotty.' Key benefits include:

• Enhanced communication efficiency between care teams
• Integration with existing Baxter solutions for automated workflows
• Support for patient and staff safety through rapid response capabilities

The device addresses communication challenges in healthcare settings, where over 60% of sentinel events are caused by communication failures according to the Joint Commission. Voalte Linq will be available in the U.S. in the second half of 2025, supporting both facility-wide and unit-specific communication in areas such as Operating Room, Emergency Department, and Labor and Delivery.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the Barclays 27th Annual Global Healthcare Conference. Joel Grade, Baxter's chief financial officer, will deliver a presentation on Wednesday, March 12, 2025 at 1:00 p.m. Eastern Time.

The presentation will be accessible through a live webcast on www.baxter.com. Interested parties can access the replay of the presentation through Monday, September 8, 2025.

Baxter International (BAX) reported Q4 2024 sales from continuing operations of $2.75 billion, up 1% reported and 2% on constant currency, exceeding guidance. Q4 U.S. GAAP diluted EPS loss was ($0.95), with adjusted EPS of $0.58 from continuing operations.

Full-year 2024 sales reached $10.64 billion, increasing 3% on both reported and constant currency basis. The company completed the sale of its Kidney Care business to Carlyle for approximately $3.4 billion in net after-tax proceeds, exceeding previous expectations of $3.15-3.25 billion.

For 2025 outlook, Baxter expects sales growth from continuing operations of 5-6% reported, and 4-5% operational. The company projects adjusted earnings from continuing operations of $2.45-2.55 per diluted share for full-year 2025.

Baxter International (NYSE:BAX) has announced its participation in the TD Cowen 45th Annual Health Care Conference on March 5, 2025. The company's CFO, Joel Grade, will deliver a presentation at 1:10 p.m. Eastern Time. A live webcast will be available on Baxter's website, with replay access through September 1, 2025.

Baxter is a global medtech leader with over 90 years of experience, providing diagnostic, critical care, nutrition, hospital, and surgical products across various healthcare settings. The company's products and digital health solutions are available in more than 100 countries, serving millions of patients, caregivers, and healthcare providers daily. Baxter continues to build on its legacy of medical breakthroughs to develop innovative healthcare solutions.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the Raymond James & Associates' 46th Annual Institutional Investors Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Monday, March 3, 2025, at 1:05 p.m. Eastern Time.

Interested parties can access the live webcast of the presentation through www.baxter.com. The presentation recording will remain available for replay until August 30, 2025.

Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the upcoming Citi - 2025 Medtech & Life Sciences Access Day. Joel Grade, Baxter's chief financial officer, will deliver a presentation on Thursday, February 27, 2025, at 1:00 p.m. Eastern Time.

The presentation will be accessible through a live webcast on www.baxter.com. For those unable to attend the live session, a replay will remain available until Tuesday, August 26, 2025.

Baxter International (NYSE:BAX) has announced a quarterly cash dividend declaration by its Board of Directors. The company will pay $0.17 per share of common stock, with an indicated annual dividend rate of $0.68 per share. The dividend will be distributed on April 1, 2025, to stockholders of record as of February 28, 2025.

Baxter International (NYSE:BAX) announced the immediate retirement of José (Joe) E. Almeida from his positions as Chair, President, and CEO. Lead Independent Director Brent Shafer has been appointed as Chair and Interim CEO, with the board initiating a comprehensive search for a permanent CEO.

The company also appointed Heather Knight as Executive Vice President and Chief Operating Officer, responsible for global operations including sales, marketing, R&D, supply chain, and medical affairs. Nancy Schlichting will assume the role of lead independent director.

Baxter recently completed the sale of its Kidney Care business to Carlyle on January 31, 2025. The company expects Q4 and full-year 2024 results to align with previous guidance, maintaining its 2025 objectives of 4-5% operational sales growth and approximately 16.5% adjusted operating margin. However, these projections don't include potential impacts from recently announced U.S. tariffs on imports from Mexico, Canada, and China.

Baxter International (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. Investors can pre-register for the call through a provided registration link. The conference call will also be accessible via webcast through Baxter's website. The company notes that the call will be recorded and is copyrighted material, requiring Baxter's permission for any recording or rebroadcasting.